Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Sampson

Showing results (371-380 of 393) with videos related to

Pageof 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant GliomaPatrick C Gedeon, Teilo H Schaller, Satish K Chitneni, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.
Journal of Neuro-Oncology|December 3, 2003
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumorsJohn H Sampson, Gamal Akabani, Gary E Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2003
Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich, David A Reardon, Terry Peery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
Pageof 40

Showing results (371-380 of 393) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant GliomaPatrick C Gedeon, Teilo H Schaller, Satish K Chitneni, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.
Journal of Neuro-Oncology|December 3, 2003
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumorsJohn H Sampson, Gamal Akabani, Gary E Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2003
Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich, David A Reardon, Terry Peery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
Pageof 40